Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated (CORT) is a healthcare company (biotechnology) based in the United States. The share price is $70.82, up 2.31% on the day, which values the company at $7.75B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.
Key facts
- Share price
- $70.82+2.31% today
- Market value
- $7.75B
- P/E ratio
- 53.2×last 12 months
- Forward P/E
- 14.2×
- Funk Score
- 59/100
- Against its own history
- Well above its usual priceusual price $35.91
- 200-week average
- $50.7140% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Corcept Therapeutics Incorporated in more detail
CORT trades at 53.2× its last twelve months' earnings, 14.2× next year's expected earnings, 8.0× sales. Measured against its own history, the price is 97% above what its usual multiples would imply ($35.91) — well above its usual price. It sits 40% above its 200-week average of $50.71.
Over the last five fiscal years Corcept Therapeutics Incorporated has compounded revenue 16.6% a year, earnings per share -0.7% a year, free cash flow -1.2% a year. Its Funk Score is 59 out of 100 (financial strength 8.9, profitability 5.3, growth 6.0, value 3.3, each out of 10).
In its favour: Altman Z in the safe zone; Five straight years of revenue growth. Worth checking: Gross margin is shrinking.
1 of the superinvestors tracked here hold CORT, including Jim Simons (1938–2024) (0.8% of the portfolio).
Superinvestors holding CORT
1 of the investors tracked here report a position in their latest 13F filing.
- Jim Simons (1938–2024) Renaissance Technologies0.76% of portfolio · $558.9M · trimmed · Q3 2026
Health Care companies of similar size
- Twist BioscienceTWST
- Protagonist TherapeuticsPTGX
- Krystal BiotechKRYS
- 10x GenomicsTXG
- HealthEquityHQY
- Rhythm PharmaceuticalsRYTM
- AlkermesALKS
- PACS GroupPACS
- Kiniksa Pharmaceuticals InternationalKNSA
- ImmunityBioIBRX
- CytokineticsCYTK
- ABIVAXABVX
Side by side:CORT vs HQY (Corcept Therapeutics Incorporated vs HealthEquity)CORT vs TXG (Corcept Therapeutics Incorporated vs 10x Genomics)CORT vs RYTM (Corcept Therapeutics Incorporated vs Rhythm Pharmaceuticals)CORT vs ALKS (Corcept Therapeutics Incorporated vs Alkermes)CORT vs PACS (Corcept Therapeutics Incorporated vs PACS Group)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Corcept Therapeutics Incorporated (CORT): questions and answers
What is CORT's P/E ratio?
Corcept Therapeutics Incorporated trades at 53.2× its last twelve months' earnings and 14.2× next year's expected earnings. At its fiscal year-ends over the past 10 years the P/E ranged from 15.7× to 103.7×, with a median of 27.1×.
What is CORT's PEG ratio?
Corcept Therapeutics Incorporated's PEG ratio is 0.81 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Corcept Therapeutics Incorporated's market cap?
Corcept Therapeutics Incorporated is valued at $7.75B at a share price of $70.82.
Is CORT overvalued or undervalued?
Against its own history, CORT is well above its usual price: the price is 97% above the $35.91 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is CORT above its 200-week moving average?
Yes. CORT is 39.7% above its 200-week average of $50.71. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Corcept Therapeutics Incorporated growing?
Over the last five fiscal years Corcept Therapeutics Incorporated's revenue grew 16.6% a year and its earnings per share -0.7% a year; over ten years revenue grew 31.2% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Corcept Therapeutics Incorporated (CORT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CORT
Underlying data: Yahoo Finance; company filings with the SEC.